By ANA PAMPLONA, PHD A new study identifies the hemodynamic variables that distinguish patients with idiopathic pulmonary arterial hypertension (PAH) from those with isolated post-capillary pulmonary hypertension (PH), a finding that will help to diagnose and treat more accurately and effectively patients with these...
BY CHARLES MOORE. Phaware group turns technology into novel, collaborative effort for pulmonary hypertension cure. The Burbank, California-based non-profit phaware is a global association dedicated to creating awareness about pulmonary hypertension through engagement and technological innovation to discover and chart the...
By ALISA WOODS, PHD Recent advances in pulmonary arterial hypertension therapy may be used for sarcoidosis-associated pulmonary hypertension A recent article suggests prostacyclin therapy, which is used for the treatment of pulmonary arterial hypertension (PAH), may also be useful for treating...
By Bruno Castro, PhD In a recent study entitled, “Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension” published in the prestigious New England Journal of Medicine, a worldwide team of researchers demonstrated that treatment combining ambrisentan and tadalafilsignificantly improves the clinical condition of Pulmonary...
By Malika Ammam, PHD In a recent collaborative research project published in the PLOS one journal entitled “Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia,” researchers suggest that patients suffering from sickle cell anemia (SCA) have higher...
By Alisa Woods, PhD Cytori Therapeutics recently published a report of 12-month data from the Scleradec-I clinical trial studying hand dysfunction in people with scleroderma. Findings from the 12 patient trial, which was led by Dr. Brigitte Granel and Dr. Guy Magalon of...
By Patricia Silva, PhD A study led by researchers at the Imperial College London in the United Kingdom was recently published in the journal Nature reporting the discovery of a gene involved in pulmonary hypertension pathology. The study is entitled “The zinc transporter ZIP12...
By Patricia Silva, PhD Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter,...
By Maureen Newman The recent announcement of positive results for the AMBITION trial testing combinatorial ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH) is bringing more attention to the need to actively recruit participants for clinical trials. Without patients and clinicians interested in...
By Patricia Inacio, PhD In a new study entitled “Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension,” researchers determined which symptoms experienced by those with pulmonary arterial hypertension are the most self-limiting and interfering with patients daily quality of...
